Prognostic significance of the number of involved areas in the early stages of Hodgkin's disease

Tubiana, M; Henry-Amar, Michel; Hayat, M.; Burgers, M; Qasim, Malik M.; Somers, R.; Sizoo, W; Schueren, Emmanuel van der

doi:10.1002/1097-0142(19840901)54:5<885::aid-cncr2820540522>3.0.co;2-b

Cited by 66 publications

(12 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…B symptoms that are known to be of clinical importance and that are included in the Ann‐Arbor classification correlate with other parameters used to predict prognosis (i.e., stage, ESR, serum albumin, and hemoglobin) 24–29. All these parameters may have their biologic correlate in the spectrum and in amount of cytokines secreted by tumor cells and surrounding lymphoid infiltrate.…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors and treatment outcome in childhood hodgkin disease

Oğuz

Karadeniz

Okur

et al. 2005

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic factors and treatment outcome in childhood hodgkin disease

Oğuz

Karadeniz

Okur

et al. 2005

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Based on the presence of adverse disease factors, HL patients can be divided into three groups: favorable early stage (stage I-II with no adverse factors), unfavorable early stage (stage I-II with any of the adverse factors), and advanced stage (stage III-IV). Adverse factors include B symptoms, enlarged mediastinal lymph nodes, extranodal involvement, and higher erythrocyte sedimentation rates [ 13 – 15 ]. The most widely used clinical indicator of risk in HL is the International Prognostic Score (IPS), which is based on the number of unfavorable prognostic factors that are present, such as age ≥ 45 years, male gender, Ann Arbor stage IV, serum albumin < 4 g/dL, hemoglobin < 10.5 g/dL, white blood cell count ≥ 15,000/mm 3 , and lymphocyte count < 600/mm 3 [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

Nomograms for predicting the overall and cancer-specific survival of patients with classical Hodgkin lymphoma: a SEER-based study

Zhang

Zeng

et al. 2017

Oncotarget

View full text Add to dashboard Cite

The aim of this study was to establish nomograms, based on significant clinicopathologic parameters, for predicting the overall survival (OS) and the cancer-specific survival (CSS) of patients with classical Hodgkin lymphoma (CHL). The data of 43,330 CHL patients, diagnosed between 1983 and 2014, were obtainedfrom the database of the Surveillance, Epidemiology, and End Results (SEER) program. These patients were randomly divided into training (n = 30,339) and validation (n = 12,991) cohorts. The Kaplan-Meier method and Cox proportional hazards regression model were used to evaluate the prognostic effects of multiple clinicopathologic parameters on survival. Significant prognostic factors were combined to build nomograms. The predictive performance of nomograms was evaluated using the index of concordance (C-index) and calibration curves. In the training cohort, on univariate and multivariate analyses, age at diagnosis, gender, race, Ann Arbor stage, and histological type significantly correlated with the survival outcomes. These characteristics were used to establish nomograms. The nomograms showed good accuracy in predicting 1-, 5-, and 10-year OS and CSS, with a C-index of 0.794 (95% confidence interval [CI], 0.789-0.799) for OS and 0.760 (95% CI, 0.753-0.767) for CSS. In the validation cohort, the C-index for nomogram-based predictions was 0.787 (95% CI, 0.779-0.795) for OS and 0.769 (95% CI, 0.758-0.780) for CSS. All calibration curves revealed excellent consistency between predicted and actual survival. In summary, novel nomograms were established and validated to predict OS and CSS for patients with CHL. These new prognostic models could aid in improved prediction of survival outcomes leading to reasonable treatment recommendations.

show abstract

“…Early stage Hodgkin's disease has a good prognosis with modern management and prolonged survival is reported in about 80% of patients (Hoppe et al, 1982;Peckham et al, 1982;Tubiana et al, 1984). A number of factors predicting for relapse and survival have been identified (Yarnold et al, 1982; Mill & Lee, 1982;Haybittle et al, 1985;, which has allowed selection of patients with poorrisk disease for treatment with combined modality therapy.…”

mentioning

confidence: 99%

Changing patterns of relapse in Hodgkin's disease

Duchesne

Crow²,

Ashley³

et al. 1989

Br J Cancer

View full text Add to dashboard Cite

Summary The patterns of early and late relapses (those occurring later than 3 years after diagnosis) in 432 patients achieving complete remission after treatment for stage I and 11 Hodgkin's disease at the Royal Marsden Hospital between 1964 and 1983 were studied to identify factors predicting for late relapse. The incidence of early relapse has fallen progressively in recent treatment eras as staging procedures and management have improved but in contrast there has been no decrease in the risk of late relapse. The incidence of late relapse was greater in patients treated with radiotherapy rather than combined modality therapy (P<0.05). However, patients who were clinically staged and treated with combined modality therapy retained as high a risk of relapse between 3 and 6 years as in years 2 and 3. The risk of late relapse was also greater in patients with stage II disease and in those without B symptoms at presentation. Patients falling into the higher risk categories for late relapse require continued close follow-up beyond 3 years to monitor for possible relapse.Early stage Hodgkin's disease has a good prognosis with modern management and prolonged survival is reported in about 80% of patients (Hoppe et al., 1982;Peckham et al., 1982;Tubiana et al., 1984). A number of factors predicting for relapse and survival have been identified (Yarnold et al., 1982; Mill & Lee, 1982;Haybittle et al., 1985;, which has allowed selection of patients with poorrisk disease for treatment with combined modality therapy. Historically the majority of patients who relapsed did so within 3 years of their primary treatment (Herman et al., 1985) but the reduction in early relapses with the development of better staging and effective therapy has increased the proportion of patients at risk of late relapse.We have undertaken a study of all adult patients with early stage Hodgkin's disease treated at the Royal Marsden Hospital between 1964 and 1983 to analyse the timing of relapse with changing management strategies and to identify factors predicting for late relapse which might determine the need for long-term follow-up. Table I. MethodsPatients were treated with either radiotherapy alone or in combined modality treatment together with single agent or combination chemotherapy. Extended field irradiation was employed in the majority (96%) of patients to a dose of 40 Gy in 20 daily fractions, reduced to 35 Gy if prior chemotherapy had been given. If combined modality therapy was employed, six courses of MVPP or ChLVPP were given, followed after an interval of 6 weeks by radiotherapy. Sixteen patients were treated with combination chemotherapy alone.Early relapse was defined .as relapse occurring within 3 years of the date of registration, with late relapses defined as those occurring beyond 3 years. All patients were followed for a minimum of 3 years so that all the early relapses were identified. Actuarial analyses of late relapses were calculated as the inverse of relapse-free survival for those patients remaining in remission at 3 y...

show abstract

Prognostic significance of the number of involved areas in the early stages of Hodgkin's disease

Cited by 66 publications

References 16 publications

Prognostic factors and treatment outcome in childhood hodgkin disease

Prognostic factors and treatment outcome in childhood hodgkin disease

Nomograms for predicting the overall and cancer-specific survival of patients with classical Hodgkin lymphoma: a SEER-based study

Changing patterns of relapse in Hodgkin's disease

Contact Info

Product

Resources

About